Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$806.14 USD

806.14
3,911,551

-12.79 (-1.56%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $801.00 -5.14 (-0.64%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up

Eli Lilly's (LLY) Q2 earnings beat estimates while sales miss. New drugs drive sales despite generic competition to key drug Cialis.

Economic and Earnings Date Deluge

Economic and Earnings Date Deluge

Mark Vickery headshot

Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More

Another busy day awaits investors here in the middle of summer: U.S.-China trade talks resume, Personal Income & Spending data is out and Q2 earnings continue their torrent.

Eli Lilly (LLY) Tops Q2 Earnings Estimates

Lilly (LLY) delivered earnings and revenue surprises of 2.74% and -0.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up

Sanofi (SNY) beats estimates for second-quarter earnings. Key immunology drug Dupixent drives sales. The company ups its earnings growth expectations for the year.

What's in Store for Array BioPharma (ARRY) in Q4 Earnings?

Array BioPharma's (ARRY) Braftovi-Mektovi combination therapy is likely to drive fourth-quarter sales.

Should You Buy Eli Lilly (LLY) Ahead of Earnings?

Eli Lilly (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Kinjel Shah headshot

Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment

AstraZeneca (AZN), Roche (RHHBY), Bristol-Myers (BMY) and Glaxo (GSK) report Q2 results. FDA approves Lilly's (LLY) nasal glucagon to treat severe hypoglycemia.

Mitchell Moore headshot

Eli Lilly (LLY) Stock Down 6.8% in 2019: Can Q2 Earnings Boost Performance?

Eli Lilly and Company (LLY) stock is down 6.8% YTD, slightly worse than a large-cap pharma average of -5.4%. Let's dive into Eli Lilly and see what to expect from its results heading into its Q2 earnings report that will be released before the market opens on Tuesday, July 30.

Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q2.

Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to Decline

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eli Lilly (LLY) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

NuCana Initiates Dosing in Phase I Study for Solid Tumors

NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.

AC Immune Initiates Phase I Study for Alzheimer's Disease

AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.

Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA

Alkermes (ALKS) plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia.

Drug Pricing Woes Linger on Repealing Drug Rebate Proposal

Investors' skepticism runs rife as Trump drops the drug rebate proposal, pushing drugmakers to take center stage with regard to the controversial drug pricing issue.

Christopher Vargas headshot

4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal

In early May, President Donald Trump announced that he would be requiring Big Pharma to list the prices of their drugs in their TV advertisements.

The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices

The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices

Court Ruling Topples Trump Order, No Price Display in TV Ads

The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.

Mark Vickery headshot

Top Stock Reports for Bank of America, Eli Lilly & Boston Scientific

Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Eli Lilly (LLY) and Boston Scientific (BSX).

Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab

Incyte (INCY) inks a licensing deal with Zai Lab to develop and commercialize INCMGA0012 for hematology and oncology indications in Greater China.

Kinjel Shah headshot

Will the Pharma Space Witness More Mega-Merger Deals in 2H?

After two mega-mergers, Bristol-Myers/Celgene and AbbVie/Allergan, in first half of 2019, it remains to be seen if more such deals are in store for the second half.

Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Pfizer's Eucrisa Proves Safety in Kids with Atopic Dermatitis

Pfizer's (PFE) Eucrisa ointment is found safe in a late-stage label expansion study for treating mild to moderate atopic dermatitis in minors aged 3 months to 2 years.

Gilead to Submit NDA for Inflammation Drug Filgotinib in '19

Gilead (GILD) is planning to submit regulatory application to the FDA seeking approval for filgotinib as a treatment for rheumatoid arthritis.